[R] representa una herramienta de gestion facil de usar para realizar esas intersantisimas oportunidades.
The purpose of the Low-Risk Patient Group of the PROACT
clinical trial is to determine if lower-risk recipients of the On-X Aortic Valve can be safely maintained with aspirin and clopidogrel (Plavix([R])).
The purpose of the PROACT
trial is to determine if patients implanted with the On-X valve can be safely maintained with reduced levels of warfarin (brand name Coumadin([R])) anticoagulation or eliminated use of warfarin altogether.
Preliminary results of the PROACT
study show that the On-X([R]) valve continues to demonstrate tolerance of low International Normalized Ratios (INR) in high-risk aortic patients as seen previously in worldwide studies.
As FIRST patients are representative of the stroke population that we consider for IA therapy today, and their results are considerably worse than those patients in PROACT
II, the case can be more clearly made that eligible patients can indeed benefit from advanced therapy," says Janardhan.
The On-X valve is presently the subject of the ground-breaking PROACT
study in the United States.
helps healthcare organizations not only to discover what has gone wrong or what may go wrong, but why - and how to reduce or eliminate undesirable events in the future.
On-X LTI), manufacturers of the On-X([R]) Prosthetic Heart Valve and On-X([R])carbon products for orthopedic implants, announced today that enrollment in the High-Risk Patient Group of the landmark PROACT
(Prospective Randomized On-X Anticoagulation Clinical Trial) is complete.
The new PROACT
Templates provide a jump start to this process by allowing past experience to be easily accessed and utilized within new analyses.
MCRI(TM)) today announced initiation of the FDA approved clinical trial PROACT
(Prospective Randomized On-X(R) Prosthetic Heart Valve Anticoagulation Clinical Trial) being conducted under an investigational device exemption (IDE) at reduced anticoagulation levels at Emory Crawford Long Hospital, Emory University in Atlanta, Georgia.
PROLYSE(TM), a recombinant prourokinase (r-proUK) thrombolytic product, has successfully completed a Phase III clinical study (the PROACT